DOCSLIB.ORG

List of Detected Drugs/Metabolites

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
List of Detected Drugs/Metabolites TITLE: Reference - Drug Screen Broad Spectrum, Urine - Drugs Included for Detection Drug Screen Broad Spectrum, Urine – Drugs Included for Detection 3-4-Methylenedioxyamphetamine Citalopram Desmethyl Ethylone 3-4-Methylenedioxyethylamphetamine Clenbuterol Famotidine 3-4- Clobazam Fenfluramine Methylenedioxymethamphetamine 6-beta-Naltrexol Clobazam Desmethyl Fentanyl 6-O-Monoacetylmorphine Clomethiazole Fentanyl Nor Acetaminophen Clomipramine Desmethyl Fexofenadine Aciclovir Clonazepam Flecainide Alprazolam Clonazepam 7-Amino Fluconazole Alprazolam alpha-hydroxy Clonidine Flunitrazepam Amantadine Clozapine Flunitrazepam 7-Amino Amiloride Clozapine N-Oxide Flunitrazepam Desmethyl Amiodarone Clozapine N-Desmethyl Fluoxetine Amitriptyline Cocaine Fluoxetine Nor Amlodipine Codeine Fluphenazine Amoxapine Codeine-6-B-glucuronide Flurazepam Amphetamine Coumatetralyl Flurazepam 2-Hydroxyethyl Aripiprazole Cyclobenzaprine Flurazepam Desalkyl Demoxepam (chlordiazepoxide Atenolol Fluvoxamine metabolite) Atorvastatin Desipramine Gabapentin Atropine Dexamethasone Galantamine Baclofen Dextromethorphan Glimepiride Benzatropine Dextrophan Glipizide Benzocaine Diazepam Haloperidol Benzoylecgonine Diazepam Nor Heroin Benzthiazide Diazepam-4-Hydroxy-Nor Hydrocodone Benzylpenicillin Diclofenac Hydromorphone Benzylpiperazine Dihydrocodeine Hydroxyzine Bisoprolol Dihydrocodeine-6-B-glucuronide Imipramine Bromazepam Dihydromorphine Indapamide Brompheniramine Dihydromorphine-3-B-glucuronide Indomethacin Bumetanide Diltiazem Irbesartan Bupivacaine Diphenhydramine Ketamine Buprenorphine Diphenhydramine Metabolite 311 Ketamine Nor Buprenorphine Glucuronide Diphenhydramine Nor Ketoprofen Bupropion OH-Metabolite Domperidone Ketorolac Buspirone Doxapram Labetalol Butylone Doxepin Lamotrigine Carbamazepine Doxepin Nor Levamisole Carbamazepine 10-11-epoxide Doxylamine Lidocaine Cetirizine Duloxetine Lidocaine Metabolite, MEGX Chlordiazepoxide Ecgoninemethylester Lisinopril Chlorpheniramine Enalapril Loperamide Chlorpromazine Ephedrine Loratidine Cimetidine Eplerenone Lorazepam Ciprofloxacin Esmolol Lormetazepam Citalopram Estazolam Losartan Effective starting 11/27/2019. Document Number: PRE.147 Version: 1.1 Page 1 of 2 TITLE: Reference - Drug Screen Broad Spectrum, Urine - Drugs Included for Detection Drug Screen Broad Spectrum, Urine – Drugs Included for Detection Ritalinic Acid (Methylphenidate Loxapine Norbuprenorphine Glucuronide metabolite) Lysergide (LSD) Normorphine Scopolamine Lysergide 2-Oxo-3-OH Norpseudoephidrine Sertraline Lurasidone Nortriptyline Sildenafil Maprotiline Nortriptylone 10-Hydroxy Sildenafil N-Desmethyl MBDB Olanzapine Sotalol MDAI Olanzapine N-Desmethyl Strychnine MDPV (3,4-Methylenedioxypyrovalerone) Ondansetron Tapentadol Medazepam Oxazepam Tapentadol N-Desmethyl Melatonin Oxcarbazepine Telmisartan Meloxicam Oxybutynin (not in Tox binder) Temazepam Melperone Oxycodone Timolol Meperidine Oxycodone Nor Tocainide Meperidine Nor Oxymorphone Tolbutamide Mephedrone Paroxetine Toresemide Mepivacaine Pentazocine Tramadol Mescaline Perphenazine Tramadol O-Desmethyl Metformin Phenazepam Trazodone Methadone Phencyclidine Triamterene Methadone Metabolite (EDDP) Phenethylamine Triazolam Methamphetamine Pheniramine Triazolam alpha-Hydroxy Methedrone Phenpromethamine Trifluoromethylphenylpiperazine Methotrimiprazine Phenylpropanolamine Trimethoprim (Levomepromazine) Methylephedrine Phenytoin Trimipramine Methylone Pioglitazone Valsartan PMA (para- Methylphenidate Vardenafil Methyoxyamphetamine) PMMA (para- Metoclopramide Venlafaxine Methoxymethamphetamine) Metolazone Prazepam Venlafaxine O-Desmethyl Metoprolol Prazosin Verapamil Midazolam Pregabalin Verapamil Nor Midazolam alpha-Hydroxy Primidone Voriconazole Mirtazapine Propoxyphene Warfarin Mirtazapine, Desmethyl Propoxyphene Nor Yohimbine Morphine Propranolol Zaleplon Pseudoephedrine (See Morphine-3-beta-D-glucuronide Ziprasidone Ephedrine) Mycophenolic Acid Psilocin Zolpidem Nalbuphine Quetiapine Zopiclone Nalorphine Quetiapine Sulfoxide Zopiclone N-Desmethyl Naloxone Quetiapine 7-Hydroxy Zopiclone N-Oxide Naloxone Nor Quinine Zuclopenthixol Naloxone N-Oxide Ramipril Naltrexone Ramiprilat Naphyrone Ranitidine Nitrazepam Repaglinide Nitrazepam 7-Amino Risperidone Norbuprenorphine Risperidone 9-Hydroxy Effective starting 11/27/2019. Document Number: PRE.147 Version: 1.1 Page 2 of 2 .
Load more

Recommended publications
  • Drug & Alcohol Testing Program
    Pottawattmie County Drug & Alcohol Testing Program Appendix A Table of Contents POLICY STATEMENT ...................................................................................................................................... 3 SCOPE ............................................................................................................................................................ 4 EDUCATION AND TRAINING .......................................................................................................................... 4 DESIGNATED EMPLOYER REPRESENTATIVE (DER): ....................................................................................... 5 DUTY TO COOPERATE ................................................................................................................................... 5 EMPLOYEE ADMISSION OF ALCOHOL AND CONTROLLED SUBSTANCE USE: (49 CFR Part 382.121) ... 6 PROHIBITED DRUGS AND ILLEGALLY USED CONTROLLED SUBSTANCES: ..................................................... 7 PROHIBITED BEHAVIOR AND CONDUCT: ...................................................................................................... 8 DRUG & ALCOHOL TESTING REQUIREMENTS (49 CFR, Part 40 & 382) ............................................... 10 DRUG & ALCOHOL TESTING CIRCUMSTANCES (49 CFR Part 40 & 382) .............................................. 12 A. Pre-Employment Testing: .................................................................................................... 12 B. Reasonable Suspicion Testing: .........................................................................................
    [Show full text]
  • The 2006 Prohibited List International Standard
    The World Anti-Doping Code THE 2006 PROHIBITED LIST INTERNATIONAL STANDARD The official text of the Prohibited List shall be maintained by WADA and shall be published in English and French. In the event of any conflict between the English and French versions, the English version shall prevail. This List shall come into effect on 1 January 2006. THE 2006 PROHIBITED LIST WORLD ANTI-DOPING CODE Valid 1 January 2006 The use of any drug should be limited to medically justified indications SUBSTANCES AND METHODS PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION) PROHIBITED SUBSTANCES S1. ANABOLIC AGENTS Anabolic agents are prohibited. 1. Anabolic Androgenic Steroids (AAS) a. Exogenous* AAS, including: 1-androstendiol (5α-androst-1-ene-3β,17β-diol ); 1-androstendione (5α- androst-1-ene-3,17-dione); bolandiol (19-norandrostenediol); bolasterone; boldenone; boldione (androsta-1,4-diene-3,17-dione); calusterone; clostebol; danazol (17α-ethynyl-17β-hydroxyandrost-4-eno[2,3-d]isoxazole); dehydrochlormethyltestosterone (4-chloro-17β-hydroxy-17α-methylandrosta- 1,4-dien-3-one); desoxymethyltestosterone (17α-methyl-5α-androst-2-en- 17β-ol); drostanolone; ethylestrenol (19-nor-17α-pregn-4-en-17-ol); fluoxymesterone; formebolone; furazabol (17β-hydroxy-17α-methyl-5α- androstano[2,3-c]-furazan); gestrinone; 4-hydroxytestosterone (4,17β-dihydroxyandrost-4-en-3-one); mestanolone; mesterolone; metenolone; methandienone (17β-hydroxy-17α- methylandrosta-1,4-dien-3-one); methandriol; methasterone (2α, 17α- dimethyl-5α-androstane-3-one-17β-ol); methyldienolone
    [Show full text]
  • The In¯Uence of Medication on Erectile Function
    International Journal of Impotence Research (1997) 9, 17±26 ß 1997 Stockton Press All rights reserved 0955-9930/97 $12.00 The in¯uence of medication on erectile function W Meinhardt1, RF Kropman2, P Vermeij3, AAB Lycklama aÁ Nijeholt4 and J Zwartendijk4 1Department of Urology, Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands; 2Department of Urology, Leyenburg Hospital, Leyweg 275, 2545 CH The Hague, The Netherlands; 3Pharmacy; and 4Department of Urology, Leiden University Hospital, P.O. Box 9600, 2300 RC Leiden, The Netherlands Keywords: impotence; side-effect; antipsychotic; antihypertensive; physiology; erectile function Introduction stopped their antihypertensive treatment over a ®ve year period, because of side-effects on sexual function.5 In the drug registration procedures sexual Several physiological mechanisms are involved in function is not a major issue. This means that erectile function. A negative in¯uence of prescrip- knowledge of the problem is mainly dependent on tion-drugs on these mechanisms will not always case reports and the lists from side effect registries.6±8 come to the attention of the clinician, whereas a Another way of looking at the problem is drug causing priapism will rarely escape the atten- combining available data on mechanisms of action tion. of drugs with the knowledge of the physiological When erectile function is in¯uenced in a negative mechanisms involved in erectile function. The way compensation may occur. For example, age- advantage of this approach is that remedies may related penile sensory disorders may be compen- evolve from it. sated for by extra stimulation.1 Diminished in¯ux of In this paper we will discuss the subject in the blood will lead to a slower onset of the erection, but following order: may be accepted.
    [Show full text]
  • The 2014 Prohibited List International Standard
    The World Anti-Doping Code THE 2014 PROHIBITED LIST INTERNATIONAL STANDARD Version 2.0 (revised 2014 version) The official text of the Prohibited List shall be maintained by WADA and shall be published in English and French. In the event of any conflict between the English and French versions, the English version shall prevail. This List shall come into effect on 1 September 2014 The revised 2014 Prohibited List 17 May 2014 THE 2014 PROHIBITED LIST WORLD ANTI-DOPING CODE Valid 1 September 2014 In accordance with Article 4.2.2 of the World Anti-Doping Code, all Prohibited Substances shall be considered as “Specified Substances” except Substances in classes S1, S2, S4.4, S4.5, S6.a, and Prohibited Methods M1, M2 and M3. SUBSTANCES AND METHODS PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION) PROHIBITED SUBSTANCES S0. NON-APPROVED SUBSTANCES Any pharmacological substance which is not addressed by any of the subsequent sections of the List and with no current approval by any governmental regulatory health authority for human therapeutic use (e.g drugs under pre-clinical or clinical development or discontinued, designer drugs, substances approved only for veterinary use) is prohibited at all times. S1. ANABOLIC AGENTS Anabolic agents are prohibited. 1. Anabolic Androgenic Steroids (AAS) a. Exogenous* AAS, including: 1-androstenediol (5α-androst-1-ene-3β,17β-diol ); 1-androstenedione (5α- androst-1-ene-3,17-dione); bolandiol (estr-4-ene-3β,17β-diol ); bolasterone; boldenone; boldione (androsta-1,4-diene-3,17-dione); calusterone; clostebol;
    [Show full text]
  • (19) United States (12) Patent Application Publication (10) Pub
    US 20130289061A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2013/0289061 A1 Bhide et al. (43) Pub. Date: Oct. 31, 2013 (54) METHODS AND COMPOSITIONS TO Publication Classi?cation PREVENT ADDICTION (51) Int. Cl. (71) Applicant: The General Hospital Corporation, A61K 31/485 (2006-01) Boston’ MA (Us) A61K 31/4458 (2006.01) (52) U.S. Cl. (72) Inventors: Pradeep G. Bhide; Peabody, MA (US); CPC """"" " A61K31/485 (201301); ‘4161223011? Jmm‘“ Zhu’ Ansm’ MA. (Us); USPC ......... .. 514/282; 514/317; 514/654; 514/618; Thomas J. Spencer; Carhsle; MA (US); 514/279 Joseph Biederman; Brookline; MA (Us) (57) ABSTRACT Disclosed herein is a method of reducing or preventing the development of aversion to a CNS stimulant in a subject (21) App1_ NO_; 13/924,815 comprising; administering a therapeutic amount of the neu rological stimulant and administering an antagonist of the kappa opioid receptor; to thereby reduce or prevent the devel - . opment of aversion to the CNS stimulant in the subject. Also (22) Flled' Jun‘ 24’ 2013 disclosed is a method of reducing or preventing the develop ment of addiction to a CNS stimulant in a subj ect; comprising; _ _ administering the CNS stimulant and administering a mu Related U‘s‘ Apphcatlon Data opioid receptor antagonist to thereby reduce or prevent the (63) Continuation of application NO 13/389,959, ?led on development of addiction to the CNS stimulant in the subject. Apt 27’ 2012’ ?led as application NO_ PCT/US2010/ Also disclosed are pharmaceutical compositions comprising 045486 on Aug' 13 2010' a central nervous system stimulant and an opioid receptor ’ antagonist.
    [Show full text]
  • UFC PROHIBITED LIST Effective June 1, 2021 the UFC PROHIBITED LIST
    UFC PROHIBITED LIST Effective June 1, 2021 THE UFC PROHIBITED LIST UFC PROHIBITED LIST Effective June 1, 2021 PART 1. Except as provided otherwise in PART 2 below, the UFC Prohibited List shall incorporate the most current Prohibited List published by WADA, as well as any WADA Technical Documents establishing decision limits or reporting levels, and, unless otherwise modified by the UFC Prohibited List or the UFC Anti-Doping Policy, Prohibited Substances, Prohibited Methods, Specified or Non-Specified Substances and Specified or Non-Specified Methods shall be as identified as such on the WADA Prohibited List or WADA Technical Documents. PART 2. Notwithstanding the WADA Prohibited List and any otherwise applicable WADA Technical Documents, the following modifications shall be in full force and effect: 1. Decision Concentration Levels. Adverse Analytical Findings reported at a concentration below the following Decision Concentration Levels shall be managed by USADA as Atypical Findings. • Cannabinoids: natural or synthetic delta-9-tetrahydrocannabinol (THC) or Cannabimimetics (e.g., “Spice,” JWH-018, JWH-073, HU-210): any level • Clomiphene: 0.1 ng/mL1 • Dehydrochloromethyltestosterone (DHCMT) long-term metabolite (M3): 0.1 ng/mL • Selective Androgen Receptor Modulators (SARMs): 0.1 ng/mL2 • GW-1516 (GW-501516) metabolites: 0.1 ng/mL • Epitrenbolone (Trenbolone metabolite): 0.2 ng/mL 2. SARMs/GW-1516: Adverse Analytical Findings reported at a concentration at or above the applicable Decision Concentration Level but under 1 ng/mL shall be managed by USADA as Specified Substances. 3. Higenamine: Higenamine shall be a Prohibited Substance under the UFC Anti-Doping Policy only In-Competition (and not Out-of- Competition).
    [Show full text]
  • Pharmacology and Toxicology of Amphetamine and Related Designer Drugs
    Pharmacology and Toxicology of Amphetamine and Related Designer Drugs U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES • Public Health Service • Alcohol Drug Abuse and Mental Health Administration Pharmacology and Toxicology of Amphetamine and Related Designer Drugs Editors: Khursheed Asghar, Ph.D. Division of Preclinical Research National Institute on Drug Abuse Errol De Souza, Ph.D. Addiction Research Center National Institute on Drug Abuse NIDA Research Monograph 94 1989 U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service Alcohol, Drug Abuse, and Mental Health Administration National Institute on Drug Abuse 5600 Fishers Lane Rockville, MD 20857 For sale by the Superintendent of Documents, U.S. Government Printing Office Washington, DC 20402 Pharmacology and Toxicology of Amphetamine and Related Designer Drugs ACKNOWLEDGMENT This monograph is based upon papers and discussion from a technical review on pharmacology and toxicology of amphetamine and related designer drugs that took place on August 2 through 4, 1988, in Bethesda, MD. The review meeting was sponsored by the Biomedical Branch, Division of Preclinical Research, and the Addiction Research Center, National Institute on Drug Abuse. COPYRIGHT STATUS The National Institute on Drug Abuse has obtained permission from the copyright holders to reproduce certain previously published material as noted in the text. Further reproduction of this copyrighted material is permitted only as part of a reprinting of the entire publication or chapter. For any other use, the copyright holder’s permission is required. All other matieral in this volume except quoted passages from copyrighted sources is in the public domain and may be used or reproduced without permission from the Institute or the authors.
    [Show full text]
  • Pentameric Ligand-Gated Ion Channel ELIC Is Activated by GABA And
    Pentameric ligand-gated ion channel ELIC is activated PNAS PLUS by GABA and modulated by benzodiazepines Radovan Spurnya, Joachim Ramerstorferb, Kerry Pricec, Marijke Bramsa, Margot Ernstb, Hugues Nuryd, Mark Verheije, Pierre Legrandf, Daniel Bertrandg, Sonia Bertrandg, Dennis A. Doughertyh, Iwan J. P. de Esche, Pierre-Jean Corringerd, Werner Sieghartb, Sarah C. R. Lummisc, and Chris Ulensa,1 aDepartment of Cellular and Molecular Medicine, Laboratory of Structural Neurobiology, Catholic University of Leuven, 3000 Leuven, Belgium; bDepartment of Biochemistry and Molecular Biology of the Nervous System, Medical University of Vienna, A-1090 Vienna, Austria; cDepartment of Biochemistry, University of Cambridge, Cambridge CB2 1QW, United Kingdom; dPasteur Institute, G5 Group of Channel-Receptor, Centre National de la Recherche Scientifique, 75724 Paris, France; eDepartment of Medicinal Chemistry, VU University Amsterdam, 1081 HV, Amsterdam, The Netherlands; fSOLEIL Synchrotron, 91192 Gif sur Yvette, France; gHiQScreen, CH-1211 Geneva, Switzerland; and hCalifornia Institute of Technology, Pasadena, CA 91125 Edited* by Jean-Pierre Changeux, Institut Pasteur, Paris Cedex 15, France, and approved September 10, 2012 (received for review May 24, 2012) GABAA receptors are pentameric ligand-gated ion channels in- marized in SI Appendix, Table S1). In addition, it has been volved in fast inhibitory neurotransmission and are allosterically suggested that the GABA carboxylate group is stabilized through modulated by the anxiolytic, anticonvulsant, and sedative-hypnotic electrostatic interactions with Arg residues on the principal and benzodiazepines. Here we show that the prokaryotic homolog ELIC complementary faces of the binding site (4, 7–9). For benzo- also is activated by GABA and is modulated by benzodiazepines diazepines, the individual contributions of residues in loops A–F with effects comparable to those at GABAA receptors.
    [Show full text]
  • Effect of Repeated MDMA Exposure on Rat Brain and Behaviour
    Effect of repeated MDMA exposure on rat brain and behaviour by Ross van de Wetering A thesis submitted in fulfilment of the requirements for the degree of Doctor of Philosophy Victoria University of Wellington, New Zealand 2020 Table of contents Absract ........................................................................................................................... 5 List of abbreviations ...................................................................................................... 7 CHAPTER 1: GENERAL INTRODUCTION ............................................................ 10 Introduction ........................................................................................................................ 10 Behavioural fundamentals of addiction ........................................................................... 12 Studying addiction ........................................................................................................... 13 Self-administration. ...................................................................................................... 14 Behavioural sensitisation. ............................................................................................ 18 Neurocircuitry of addiction ............................................................................................... 20 Ventral tegmental area and nucleus accumbens .............................................................. 20 Dopamine and reinforcement. .....................................................................................
    [Show full text]
  • Journal of Pharmaceutical and Pharmacological Sciences Jaithliya T
    Journal of Pharmaceutical and Pharmacological Sciences Jaithliya T. J Pharma Pharma Sci 02: JPPS 122. Case Report DOI:10.29011/2574-7711.100022 Ashwagandha-The Nature’s Gift to Mankind Tanvay Jaithliya* Department of Pharmacy, Mewar University, Gangrar (Chittorgarh), India *Corresponding author: Jaithliya T, Department of Pharmacy, Mewar University, Gangrar (Chittorgarh) India. Tel: +91 01471291148; E-mail: [email protected] Citation: Jaithliya T (2017) Ashwagandha-The Nature’s Gift to Mankind. J Pharma Pharma Sci 02: 122. DOI: 10.29011/2574-7711.100022 Received Date: 15 March, 2017; Accepted Date: 10 April, 2017; Published Date: 17 April, 2017 Withania somnifera commonly known as Ashwagandha, In- Sindh, Gujarat and Rajasthan. It is also found in Nepal, China and dian Ginseng, poison gooseberry or winter cherry is a plant in the Yemen. solanaceae family or night shade family. It is used as one of the most powerful herbs in Ayurvedic healing, has been used since ancient times for a wide variety of conditions, and is most well- known for its restorative benefits. Traditionally, it is believed that a person who consumes this herbal medicine will gain horse like strength and vitality. Pathology Ashwagandha is prone to several pests and diseases. Leaf spot disease caused by alternariaalternata Is the most prevalent disease, which is most severe in the plains of Punjab, Haryana, Jammu and Kashmir and Himachal Pradesh? Bio deterioration of its pharmaceutically active components during leaf spot disease Description has been reported. This species is short, tender perennial shrub growing 14-30 Culinary Use inches tall. Leaves are dull green, elliptic, usually up to 10-12 cm long.
    [Show full text]
  • Partial Agreement in the Social and Public Health Field
    COUNCIL OF EUROPE COMMITTEE OF MINISTERS (PARTIAL AGREEMENT IN THE SOCIAL AND PUBLIC HEALTH FIELD) RESOLUTION AP (88) 2 ON THE CLASSIFICATION OF MEDICINES WHICH ARE OBTAINABLE ONLY ON MEDICAL PRESCRIPTION (Adopted by the Committee of Ministers on 22 September 1988 at the 419th meeting of the Ministers' Deputies, and superseding Resolution AP (82) 2) AND APPENDIX I Alphabetical list of medicines adopted by the Public Health Committee (Partial Agreement) updated to 1 July 1988 APPENDIX II Pharmaco-therapeutic classification of medicines appearing in the alphabetical list in Appendix I updated to 1 July 1988 RESOLUTION AP (88) 2 ON THE CLASSIFICATION OF MEDICINES WHICH ARE OBTAINABLE ONLY ON MEDICAL PRESCRIPTION (superseding Resolution AP (82) 2) (Adopted by the Committee of Ministers on 22 September 1988 at the 419th meeting of the Ministers' Deputies) The Representatives on the Committee of Ministers of Belgium, France, the Federal Republic of Germany, Italy, Luxembourg, the Netherlands and the United Kingdom of Great Britain and Northern Ireland, these states being parties to the Partial Agreement in the social and public health field, and the Representatives of Austria, Denmark, Ireland, Spain and Switzerland, states which have participated in the public health activities carried out within the above-mentioned Partial Agreement since 1 October 1974, 2 April 1968, 23 September 1969, 21 April 1988 and 5 May 1964, respectively, Considering that the aim of the Council of Europe is to achieve greater unity between its members and that this
    [Show full text]
  • Pharmacological Treatments in Insomnia
    Pharmacological treatments in insomnia Sue Wilson Centre for Neuropsychopharmacology, Division of Brain Sciences, Imperial College, London Drugs used in insomnia Licensed for insomnia •GABA-A positive allosteric modulators •melatonin (modified release) •promethazine •diphenhydramine •doxepin (USA) Unlicensed prescribed frequently •antihistamines (and OTC) •antidepressants Sometimes prescribed drugs for psychosis Some GABA-A positive allosteric modulators Drugs acting at the GABA-A benzodiazepine receptor zopiclone zolpidem zaleplon benzodiazepines eg temazepam, lorazepam (safe in overdose, as long as no other drug involved) Drugs acting at the barbiturate/alcohol receptor chloral hydrate/chloral betaine clomethiazole (dangerous in overdose) GABA calms the brain Gamma aminobutyic acid (GABA) is the main inhibitory transmitter in the mammalian central nervous system. It plays the principal role in reducing neuronal excitability and its receptors are prolific throughout the brain, in cortex, limbic system, thalamus and cerebellum sedative Increase anticonvulsant GABA anxiolytic function ataxia, memory effects Effects of GABA-A positive allosteric modulators •These drugs enhance the effect of GABA, the main inhibitory neurotransmitter in the brain •They all produce sedation, sleep promotion, ataxia, muscle relaxation, effects on memory, anticonvulsant effects •Therefore for insomnia the duration of action of the drug is important – these effects are unwanted during the day Effects of these GABA-ergic drugs on sleep EEG/PSG • Appearance of
    [Show full text]